Investing.com-- Google’s (NASDAQ: GOOGL) artificial intelligence research arm, DeepMind, has imposed stricter controls on the ...

Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ...

Google’s AI arm led by Demis Hassabis makes it harder for its researchers to publish studies in major change in approach ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Dr David Baker's Nobel Prize-winning breakthrough of designing new proteins has the potential to stop cancers, pandemics, fix ...

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict ...

The drug discovery company, which has partnerships with Eli Lilly and Novartis, is developing AI models to design drugs and ...

The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue ...

The company, which uses artificial intelligence to develop new treatments, now counts the venture capital firm Thrive Capital ...

The funding is set to accelerate the development of Isomorphic’s AI drug design engine and advance clinical programmes.

Google spinoff Isomorphic Labs raised $600 million in its first external funding round as the company looks to apply ...